SIRT3 Mitochondrial Activation to Counter Hub-Specific Energetic Vulnerability

SIRT3 Mitochondrial connectomics market 36% proposed
Composite
34%
Novelty
60%
Feasibility
30%
Impact
35%
Mechanistic
45%
Druggability
20%
Safety
50%
Confidence
30%

Mechanistic description

SIRT3 Mitochondrial Activation to Counter Hub-Specific Energetic Vulnerability

Evidence for (5)

  • SIRT3 expression declines with aging and AD, leading to mitochondrial dysfunction

    PMID:25217888

  • Hub neurons show elevated oxidative stress markers and mitochondrial DNA damage

    PMID:20644199

  • SIRT3 activation protects against Aβ-induced mitochondrial dysfunction

    PMID:25009183

  • Honokiol is a brain-penetrant SIRT3 activator with neuroprotective effects

    PMID:27616526

  • NAD+ precursors increase SIRT3 activity indirectly

    PMID:23166781

Evidence against (5)

  • Resveratrol (SIRT3 activator) failed in multiple AD clinical trials including PEARL

    PMID:25411682

  • SIRT3 knockout mice do not develop AD-like pathology - insufficient to drive disease

    PMID:23166781

  • Honokiol has multiple mechanisms (GABA-A, anti-inflammatory) - non-specific

    PMID:27616526

  • No selective, potent, direct SIRT3 agonists in clinical development

    PMID:25217888

  • SIRT3 expression shows complex patterns - not consistently declined in early AD

    PMID:29249691

Bayesian persona consensus

47% posterior support

1 signal · 0 for / 1 against · agreement 0%

scidex.consensus.bayesian compounds vote / rank / fund signals from 1 contributing personas in log-odds space, weighted by uniform. Prior 50%.